IDEAYA Biosciences, Inc.
$25.56-$0.61 (-2.3%)
Last close · Data as of Nov 20, 2026
- Market cap
- $2.6B
- P/E
- -22.6x
- EV / EBITDA
- -16.0x
- Revenue
- $218.7M
- Net margin
- -52.0%
- ROCE
- -15.2%
Price chart
Technical chartScreen technicals →-22.9% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -27.7%
- 3M
- -34.6%
- 6M
- -13.8%
- 1Y
- -22.9%
- 5Y
- +10.1%
52-week range
Day change -$0.61 (-2.3%) from $26 to $26 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in IDYA, bought on each weekday since 2021.
News & filings
What IDEAYA Biosciences filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 114 million US dollars in fiscal 2025.
Strengths (1)
- Revenue more than doubled in fiscal 2025.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
Read moreShow less
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer driven by GNAQ/11 mutations, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor that is in a Phase 1 clinical trial for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 dose optimization trial; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate the efficacy and safety of IDE849, an antibody-drug conjugate. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Shares outstanding
- 87.8M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $2.6B
- P/E
- -22.6x
- P/B
- 2.5x
- EV / EBITDA
- -16.0x
- EV / Sales
- 11.4x
- P/S
- 11.7x
- 52-week high
- $42.48
- 52-week low
- $25.56
Profitability
- Operating margin
- -72.8%
- Net margin
- -52.0%
- EBITDA margin
- -70.7%
- ROE
- -11.1%
- ROCE
- -15.2%
- ROIC
- -13.4%
- ROA
- -10.2%
- Asset turnover
- 0.20
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $218.7M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 3024.4%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 62.5%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -58.6%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$73.5M
Solvency
- Current ratio
- 11.34
- Debt / Equity
- 0.03
- Debt / Assets
- 0.03
- CFO / Net profit
- 0.63
- Cash / Market cap
- 4.4%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $218.7M |
| Gross profit | $218.7M |
| Operating expenses | $378.0M |
| Research and development | $314.7M |
| Selling, general and administrative | $63.3M |
| Operating income | -$159.3M |
| Interest and other | $45.6M |
| Pretax income | -$113.7M |
| Tax and other | $0.00 |
| Net income | -$113.7M |
Revenue and net profit
Revenue grew 3024.4% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $50.9M | -$58.7M |
| FY2023 | $23.4M | -$113.0M |
| FY2024 | $7.0M | -$274.5M |
| FY2025 | $218.7M | -$113.7M |
Cash flows
FY2025: -$71.1M from operations, -$73.5M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$87.2M | -$90.6M |
| FY2023 | -$115.2M | -$117.6M |
| FY2024 | -$247.6M | -$251.4M |
| FY2025 | -$71.1M | -$73.5M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $218.7M+3,024.4%1Y
- EBITDA
- -$154.7M
- Net profit
- -$113.7M
- Cash from operations
- -$71.1M
- Free cash flow
- -$73.5M
- Revenue CAGR, 3Y
- 62.5%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $218.7M | -$154.7M | -$113.7M | -$73.5M | -11.1% | +3024.4% | -58.6% |
Monthly returns
Month-by-month returns of IDYA across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.1B |
| Current assets | $666.7M |
| Non-current assets | $442.6M |
| Liabilities | $86.4M |
| Current liabilities | $58.8M |
| Non-current liabilities | $27.6M |
| Equity | $1.0B |
| Paid-in capital | $1.8B |
| Retained earnings | -$736.5M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; IDYA highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Disc Medicine, Inc., Definium Therapeutics, Inc., Vera Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| IDEAYA Biosciences, Inc.IDYAthis company | $2.6B | -22.6x | 2.5x | -11.1% | -16.0x |
| Arcutis Biotherapeutics, Inc.ARQT | $2.7B | -170.1x | 14.5x | -8.5% | 1582.5x |
| Disc Medicine, Inc.IRON | $2.7B | -12.8x | 3.7x | -28.7% | -12.8x |
| Definium Therapeutics, Inc.DFTX | $2.7B | -14.6x | 8.1x | -55.3% | -13.8x |
| Alumis Inc.ALMS | $2.6B | -10.7x | 8.6x | -80.8% | -5.7x |
| Tarsus Pharmaceuticals, Inc.TARS | $2.6B | -39.1x | 7.6x | -19.3% | -45.8x |
| Guardian Pharmacy Services, Inc.GRDN | $2.6B | 52.5x | 12.6x | 23.9% | 26.5x |
| Heartflow, Inc.HTFL | $2.5B | -21.3x | 8.3x | -38.8% | -26.4x |
| Vera Therapeutics, Inc.VERA | $2.4B | -8.0x | 4.0x | -49.6% | -7.3x |
| Peer median | — | -13.7x | 8.2x | -33.8% | -10.0x |
Year-to-date ROI
IDYA since 1 January, against earlier years.
Historical volatility
IDYA's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -122.7% |
| FY2023 | -575.0% |
| FY2024 | -4671.1% |
| FY2025 | -72.8% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $218.7M |
| Operating expensesOperating Expense | $378.0M |
| Research and developmentResearch And Development | $314.7M |
| Selling, general and administrativeSelling General And Administration | $63.3M |
| Total expensesTotal Expenses | $378.0M |
| Operating incomeOperating Income | -$159.3M |
| Interest and other | |
| Pretax incomePretax Income | -$113.7M |
| Tax | |
| Net incomeNet Income | -$113.7M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.1B |
| Current assetsCurrent Assets | $666.7M |
| Non-current assetsTotal Non Current Assets | $442.6M |
| LiabilitiesTotal Liabilities Net Minority Interest | $86.4M |
| Current liabilitiesCurrent Liabilities | $58.8M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $27.6M |
| EquityTotal Equity Gross Minority Interest | $1.0B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$71.1M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$71.1M |
| Net income, continuing operationsNet Income From Continuing Operations | -$113.7M |
| Depreciation and amortisationDepreciation And Amortization | $4.6M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $4.6M |
| Depreciation | $4.6M |
| Amortization of securitiesAmortization Of Securities | -$10.0M |
| Stock-based compensationStock Based Compensation | $46.1M |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | — |
| Change in working capitalChange In Working Capital | $1.9M |
| Investing cash flowInvesting Cash Flow | $70.0M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $70.0M |
| Capital expenditureCapital Expenditure | -$2.4M |
| Purchase of PP&EPurchase Of PPE | -$2.4M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$2.4M |
| Purchase of investmentsPurchase Of Investment | -$607.9M |
| Sale of investmentsSale Of Investment | $680.2M |
| Net investment purchases and salesNet Investment Purchase And Sale | $72.3M |
| Financing cash flowFinancing Cash Flow | $29.8M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $29.8M |
| Shares issuedIssuance Of Capital Stock | $24.9M |
| Common stock issuedCommon Stock Issuance | $24.9M |
| Net common stock issuedNet Common Stock Issuance | $24.9M |
| Stock options exercisedProceeds From Stock Option Exercised | $4.9M |
| Preferred stock issuancePreferred Stock Issuance | — |
| Net preferred stock issuanceNet Preferred Stock Issuance | — |
| Change in cashChanges In Cash | $28.7M |
| Cash at the start of the yearBeginning Cash Position | $85.2M |
| Cash at the end of the yearEnd Cash Position | $113.8M |
| Free cash flowFree Cash Flow | -$73.5M |
| Supplemental |
Learn while you research
Academy chapters picked for IDEAYA Biosciences, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing3024% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read